newsfilter
← Earnings
Earnings Releases·

Sionna Therapeutics — Third Quarter 2026 Earnings Summary

  • Net loss widened to $32.4 million (vs. $20.3 million YoY) with R&D and G&A expenses rising to $22.0 million and $12.8 million respectively, driven by development costs, stock-based compensation, and restructuring charges.
  • Cash and marketable securities decreased to $249.8 million as of September 30, 2026, down from $310.3 million at year-end 2025, though management projects the current runway will fund operations into the second half of 2029.
  • Strategic focus narrowed to the SION-451 + SION-2222 dual combination, which will enter the AscenSION CF Phase 2 proof-of-concept trial in Q1 2027, while SION-719 development was halted following the PreciSION CF Phase 2a failure.
  • A 46% workforce reduction implemented in September 2026 accompanied other cost-saving measures to align resources with the prioritized program and extend the operating runway.
Company
SIONNA THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology